Popular weight-loss drugs show promising new power against debilitating migraines
In a small study, a GLP-1 drug shrank the number of days people spent with a migraine by almost half in a given month.
Presented at the European Academy of Neurology Congress in Helinski, Finland, on June 21, the results suggest promising future uses of the popular obesity and diabetes drugs.
Who Should Be Taking Weight-loss Drugs? Doctors Share Best Candidates
Nearly 40 million Americans deal with migraines, according to the World Health Organization (WHO) — and for many, they're more than just a headache.
Migraines are the second-leading cause of disability worldwide, the above agency states, with symptoms including severe headaches, nausea and sensitivity to light often disrupting daily activities.
Read On The Fox News App
Previous studies have shown that GLP-1s can reduce pressure inside the skull, which is a possible cause of migraines, according to multiple health organizations.
Neurologist and study lead Simone Braca of the University of Naples Federico II in Italy, along with his colleagues, explored whether liraglutide, an earlier version of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), could help migraine sufferers.
Thirty-one adults, 26 of them women, got daily injections of liraglutide for 12 weeks. The participants, who all met the criteria for obesity, also continued to take their current migraine medications.
At the start of the experiment, participants reported headaches about 20 days out of a month. After 12 weeks of liraglutide, the average number dropped to about 11 days.
"Most patients felt better within the first two weeks and reported quality of life improved significantly," said Braca in a press release for the study, which was published in the journal Headache last month.
The relief from migraines lasted for the full three-month observation period, the researcher noted, although weight loss was "modest and statistically non-significant."
Participants' weight stayed about the same during the trial, suggesting that the headache reductions weren't tied to weight loss.
Weight-loss Medications May Also Benefit Common Medical Problem, Study Finds
"Liraglutide is a 'middle-aged' GLP-1, with Ozempic and Mounjaro being newer," Dr. Sue Decotiis, a triple board-certified weight loss specialist in New York City, told Fox News Digital.
Decotiis, who was not involved in the study, said that liraglutide is not as effective as its newer cousins for weight loss or diabetes, and is not frequently used for these purposes.
"Many pharmacies are not even stocking it due to declining demand, yet it gets into the brain well enough to reduce migraines," she noted.
The trial didn't include a comparison group, and participants and researchers all knew that everyone received liraglutide, the researchers noted.
Mild gastrointestinal side effects (mainly nausea and constipation) occurred in 38% of participants, but did not lead to treatment discontinuation.
Further research may include other groups, such as control groups and people without obesity, to compare the drug's effects.
"The study was very small," Decotiis confirmed to Fox News Digital.
Given its size and brief duration, the findings could be limited until further research is conducted, according to the expert.
Click Here To Sign Up For Our Health Newsletter
The researchers also tested only one drug, liraglutide, "which is not used as frequently in the general population as semaglutide or tirzepatide are," Decotiis added.
For more Health articles, visit www.foxnews.com/health
Next, the team is planning a randomized, double-blind trial that will also measure pressure inside the skull.
"We also want to determine whether other GLP-1 drugs can deliver the same relief, possibly with even fewer gastrointestinal side effects," Braca said in the same press release.Original article source: Popular weight-loss drugs show promising new power against debilitating migraines
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Alligator Bioscience Provides Highlights from R&D Event 2025
LUND, SE / / August 20, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, provides key highlights from its R&D event held on 19 August 2025. The event featured presentations from Alligator's management and scientific leadership, outlining Alligator's clinical progress, upcoming milestones, and strategic outlook. Key takeaways from the event include: Mitazalimab - Phase 3 readiness : Long-term follow-up data continue to demonstrate encouraging overall survival in metastatic pancreatic cancer, supporting the confirmed regulatory path and planned initiation of a Phase 3 trial. Scientific insights : New translational biomarker data further expand and strengthen the rationale for mitazalimab in pancreatic cancer and other solid tumors, underscored by myeloid and T-cell activation and their correlation with improved clinical outcomes. Trial completion and CMC status: The final, 30-month, data read-out from OPTIMIZE-1 is expected during Q3 2025. The trial will thereafter be finalized, with mitazalimab being provided to patients still on treatment, and sites with ongoing patients remain open under limited, risk-based monitoring; manufacturing of Phase 3 material has been successfully completed. Investigator-initiated trials (IITs) : Based on the significant investigator interest Alligator is engaged in a number of externally funded exploratory and Phase 2 clinical trials with mitazalimab across pancreatic, gastrointestinal and other solid tumors to expand mitazalimab's future clinical use. Individual trials are expected to start during H2 2025 and the first half of 2026. Pipeline updates : The HER2 antibody HLX22 (developed by Chinese Henlius) has entered a global Phase 3 trial in gastric cancers. Alligator expects to receive the next development milestone within 6-12 months, and estimates that its share of the future royalties will amount to SEK 150-400 million annually. Strategic outlook : With a reduced burn-rate, Alligator is well positioned to advance mitazalimab into registrational trials together with a partner, and in parallel explore additional development options for the asset. Together mitazalimab and HLX22 represent a significant financial upside for Alligator. Other pipeline assets and technologies represent additional future development and income opportunities. A replay of the event is available through >>this link<< . For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 12:15 p.m. CEST on 20 August 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . Attachments Alligator Bioscience provides highlights from R&D event 2025 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire
CNN
23 minutes ago
- CNN
UK regulator bans shower gel ad for perpetuating racial stereotypes
UK regulators have banned a TV commercial for Sanex shower gel after ruling that it 'could be interpreted as suggesting that white skin was superior to black skin.' The Advertising Standards Authority (ASA) acted after receiving complaints about the ad from two people 'who believed the ad perpetuated negative stereotypes about people with darker skin tones,' it said in a statement Wednesday. The spot, which aired in June, featured a Black model whose skin is covered with red scratch marks and another covered with a cracked material that looks like clay. 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24-hour hydration feel,' a voice-over said, accompanying video of a White woman showering. 'Relief could be as simple as a shower,' it added. US consumer products company Colgate-Palmolive, which owns the Sanex brand, said the fact that the ad featured models with different skin tones demonstrated its commitment to diversity, according to the ASA's statement. The regulator said Colgate-Palmolive believed 'the depiction of diverse models in the ad, either experiencing skin discomfort or post-product relief, was utilised in a 'before and after' scenario to show their product was suitable and effective for all, rather than as a comparison based on race or ethnicity.' Clearcast, a company that checks whether TV commercials follow the UK Code of Broadcast Advertising before they can be aired, also said the ad demonstrated the inclusivity of Sanex. While the ASA accepted the argument that the ad showed 'before and after' scenarios to demonstrate the effectiveness of the product, it ruled that its structure was problematic. 'It was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved,' the statement said. 'That could be interpreted as suggesting that white skin was superior to black skin,' it added, while acknowledging that 'we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers.' The ASA added that it had concluded the ad had breached the broadcast advertising code and was likely to cause serious offense. CNN has contacted Colgate-Palmolive for comment.
Yahoo
2 hours ago
- Yahoo
āshibio licences vantictumab for rare bone disorder
Biotechnology company āshibio has entered an exclusive licencing agreement with Mereo BioPharma for the monoclonal antibody, vantictumab, to treat a rare bone disorder. The agreement aims to facilitate antibody development for the autosomal dominant osteopetrosis type 2 (ADO2) bone condition that currently lacks approved therapies. āshibio will oversee clinical development of vantictumab globally for both adult and paediatric patients. Mereo has granted exclusive rights to āshibio for the development and commercialisation in the US and other regions outside of Europe, where Mereo retains commercial rights. ADO2, also referred to as Albers-Schönberg disease, is a genetic disorder characterised by reduced osteoclast function, leading to dense and brittle bones. It is linked to mutations in the chloride channel 7 (CLCN7) gene, with an incidence rate of one in 20,000 births. Āshibio CEO Pankaj Bhargava stated: 'People living with autosomal dominant osteopetrosis type 2 face a lifetime of bone-related complications resulting in significant morbidity, multiple surgical procedures, chronic pain and impaired quality of life – yet patients have no approved therapy to address the disease. 'Bringing vantictumab into our pipeline reflects our commitment to advancing therapies for rare skeletal conditions and improving the lives of those affected by serious bone disorders.' Vantictumab functions by selectively binding to specific frizzled (Fzd) receptors and inhibiting Wnt (wingless-related integration) signalling pathways. Initially developed for cancer treatment, it has undergone clinical trials in oncology showing a favourable safety and pharmacokinetic profile. Previous studies have generated biomarker data that support the efficacy of vantictumab on osteoclast function, which aids in reducing risks associated with the clinical programme and allows āshibio to expedite the advancement of vantictumab into clinical trials for ADO2. "āshibio licences vantictumab for rare bone disorder" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
